RARE DISEASE
Meningococcal meningitis
Meningococcal meningitis
Meningococcal meningitis
Drug discovery
2
drugs
With orphan designations
Overview
Meningococcal meningitis, caused by Neisseria meningitidis, is a life-threatening bacterial infection of the meninges characterized by sudden fever, neck stiffness, altered mental status, and petechial/purpuric rash [1][2][6]. Rapid progression necessitates immediate intravenous antibiotics (e.g., ceftriaxone, vancomycin), droplet precautions, and post-exposure prophylaxis for close contacts [1][3][16]. Vaccination (MenACWY/MenB) remains critical for prevention in high-risk populations [6][17].
Burden
Case fatality rate: 10–15%; 20% of survivors experience permanent sequelae (e.g., hearing loss, limb amputation) [6][9][11].
Global burden: 236,000 deaths (2019), with N. meningitidis contributing 13.6% of meningitis-related deaths [4].
US trends: 438 cases in 2023 (highest since 2013), driven by serogroup Y [2][17].
Therapies
Empiric IV antibiotics (ceftriaxone ± vancomycin/ampicillin) adjusted for age/risk factors [3][13].
Dexamethasone adjunct for suspected bacterial meningitis to reduce neurologic complications [3].
Post-exposure prophylaxis (rifampin, ciprofloxacin, or ceftriaxone) for close contacts and exposed healthcare workers [1][16].
Categories: rare neurological diseases
Research Papers
1,812 drug discovery papers about Meningococcal meningitis, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,812 drug discovery papers about Meningococcal meningitis, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-17 | Meningitis Vaccine Delivery Strategies and Their Health Impact in Africa: A Scoping Review to Inform the Introduction of New Vaccines.
IntroductionVaccination has played a pivotal role in mitigating the burden of meningitis in the African meningitis belt. However, outbreaks have continued due to the emergence of new serogroups, and logistical barriers. This scoping review synthesizes published evidence on health impact of meningitis vaccine delivery strategies to guide policy and programmatic decision-making and maximize the impact of the new meningitis vaccines.MethodsThe review followed PRISMA extension for scoping reviews. Eligible studies published between 2004 and 2024 in English or with an English translation examining the use of meningitis vaccines and delivery strategies across Africa were included. A systematic search of online databases was conducted using predefined search terms, and following screening of 1,026 articles, 20 were included in the review. Data on relevant themes were extracted into an excel spreadsheet and analyzed guided by PAGER framework.ResultsThe review found limited real-world evidence on meningitis vaccine delivery strategies, with many studies relying on modelling approaches. Findings showed that routine infant immunization and campaign-based strategies have been used to deliver meningitis vaccines in Africa. Compared to routine vaccination, campaign-based strategies were shown to achieve high coverage rates (∼95%), high risk reduction (71%) and high decline in suspected cases (82%). However, routine immunization combined with an initial catch-up campaign was cost-effective, saving USD1.3 for every USD1 invested. The use of the Controlled Temperature Chain (CTC) system for Men A conjugate vaccines enhanced accessibility and cost-effectiveness, particularly for remote facilities lacking cold chain infrastructure. Integrated campaigns were more cost-effective than stand-alone campaigns. Combining campaigns with routine immunization resulted in significant reduction of disease burden, despite potential disruptions during mass vaccination campaigns.ConclusionsCombining routine and campaign-based immunization strategies will enhance the impact of the new meningitis vaccines. There is need for more real-world implementation and cost-effectiveness research from Africa.
2026-08-12 | Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study.
Meningococcal meningitis remains a major public health challenge in Africa's meningitis belt despite the successful elimination of serogroup A epidemics following MenAfriVac introduction. Outbreaks caused by serogroups C, W, and X persist. NmCV-5, a pentavalent conjugate vaccine targeting serogroups A, C, W, Y, and X, was prequalified by WHO in 2023 and used in Niger during reactive vaccination campaigns in 2024. We conducted a matched case-control study in six health districts in Niger (Niamey IV and Magaria) to estimate NmCV-5 effectiveness against meningococcal meningitis. Cases were individuals with PCR-confirmed meningococcal meningitis, aged 1-19 years, resident in the vaccination campaign area, and presenting with symptom onset ≥10 days post-campaign. Enrollment took place between May 2024 and July 2025. Four age-, sex-, and residence-matched community controls were enrolled per case. Vaccination status was verified by patient-retained vaccination card when available or self-reported. Logistic regression was used to calculate crude and adjusted vaccine effectiveness (VE). 17 confirmed cases (14 NmC, 3 NmW) and 68 matched community controls were enrolled in the study. Seven cases (41%) and 58 controls (86%) reported NmCV-5 vaccination; vaccination status of all cases and 8 of 58 (14%) controls was confirmed by vaccination card. Crude VE against all meningococcal meningitis was 88% (95% CI: 62-96), and against NmC specifically was 86% (95% CI: 50-96). Adjusted for household crowding and history of recent respiratory infections, VE was 92% (95% CI: 72-98) overall and 91% (95% CI: 63-98) for NmC. Sensitivity analyses confirmed robustness of estimates under extreme assumptions. NmCV-5 demonstrated high effectiveness against circulating meningococcal strains NmC and NmW in real-world outbreak conditions. Limitations include small sample size, reliance on self-reported vaccination status, and absence of cases from other serogroups. Further studies should assess long-term impact on carriage and effectiveness against invasive disease across all targeted serogroups.
2026-08-06 | A Carriage-Structured Model of Meningococcal Meningitis: Backward Bifurcation, Seasonal Recurrence, and the Reach of Conjugate-Vaccine Strategies in the African Meningitis Belt
Epidemic meningococcal meningitis in the African meningitis belt recurs on two superimposed timescales: a sharp annual dry-season peak and irregular multi-annual epidemics separated by five to twelve years. Because invasive disease is a rare, epidemiologically dead-end outcome of asymptomatic nasopharyngeal carriage, transmission models built on the standard susceptible-infectious template misrepresent the driving process. We formulate a deterministic carriage-structured model in which only carriers transmit, immunity against carriage re-acquisition is leaky, and a conjugate vaccine protects imperfectly and wanes. We show analytically that the basic reproduction number \( R_0 \) is a property of carriage transmission and is decoupled, to first order, from disease incidence, so that reproduction numbers inferred from case notifications estimate the wrong quantity. Using the Castillo-Chavez-Song centre manifold method, we derive, in closed form, the condition for backward bifurcation and prove that it is governed by a threshold \( \varepsilon^\ast \) on carriage-blocking immunity, not by vaccine leakiness or by case-management capacity: the invasive-disease compartment is provably absent from the bifurcation condition. Under seasonal forcing we characterize, through Floquet analysis and two-parameter continuation, the region of immunity-waning and seasonal-amplitude space in which multi-annual recurrence arises, confirming that annual forcing alone cannot generate it. A scenario analysis calibrated to published belt parameter ranges quantifies the burden averted by routine infant immunisation, catch-up campaigns, and improved carriage efficacy, and shows that whether sustained immunisation eliminates epidemics or merely postpones them depends on the same carriage-efficacy threshold that governs bistability.
2026-07-28 | Recent advances in the development of a vaccine to target meningococcal serogroup X.
Serogroup X has emerged as an important cause of invasive meningococcal disease across Sub-Saharan Africa. Recent advances in serogroup X vaccines were reviewed. Early vaccine development efforts focused on outer membrane vesicle-based approaches. The growing epidemiological importance of serogroup X accelerated the development of serogroup X conjugate vaccines. Building on the success of MenAfriVac, PATH and the Serum Institute of India Pvt. Ltd. developed NmCV-5 (MenFive), the first pentavalent meningococcal conjugate vaccine targeting serogroup X. NmCV-5 achieved World Health Organization (WHO) pre-qualification in 2023, enabling deployment across Sub-Saharan Africa. A second pentavalent vaccine, EuNmCV-5, developed by Eubiologics is advancing through clinical development, while an additional candidate from Sinovac Biotech is entering early phase evaluation. These advances representative a major milestone in meningococcal disease prevention. Within the last fifteen years significant vaccine developments have been made to combat serogroup X. With NmCV-5 attaining WHO pre-qualification, strategies for its implementation within Sub-Saharan Africa are being devised. Only one vaccine is currently available in Sub- Saharan Africa, but trials of a second pentavalent ACWYX conjugate vaccine are ongoing. Carriage studies and disease surveillance are crucial to monitor serogroup X vaccine effectiveness.
2026-07-14 | Meningococcal meningitis in India: An expert consensus on use of MCVs.
Invasive meningococcal disease (IMD) is a significant but under-recognized public health challenge in India, marked by rapid progression, high mortality, and severe sequelae. This consensus document, developed from literature review, outbreak analyses, and deliberations by 14 Indian experts, highlights outbreaks from 1966 (Delhi: 616 cases, case fatality ration: CFR 20.9%) to 2022-2023 (Kolkata). Serogroup A remains predominant, with emerging serogroups C, W, and Y. Systematic review evidence shows 12.1% prevalence in epidemics (CFR 12.8%) and 0.76% in endemic settings (CFR 3.0%), though true burden is underestimated due to weak surveillance. IMD shows bimodal age distribution, highest in children < 5 y (61.8%) and adolescents. MenACWY conjugate vaccines show 95.7-99.5% seroprotection across serogroups. Experts recommend vaccination at 9-12 months with booster at 10-11 y, mandatory reporting, sentinel surveillance, and clinician awareness. The roadmap stresses awareness, short-term surveillance, and long-term data generation toward National Immunization Program inclusion.
2026-08-17 | Meningitis Vaccine Delivery Strategies and Their Health Impact in Africa: A Scoping Review to Inform the Introduction of New Vaccines.
IntroductionVaccination has played a pivotal role in mitigating the burden of meningitis in the African meningitis belt. However, outbreaks have continued due to the emergence of new serogroups, and logistical barriers. This scoping review synthesizes published evidence on health impact of meningitis vaccine delivery strategies to guide policy and programmatic decision-making and maximize the impact of the new meningitis vaccines.MethodsThe review followed PRISMA extension for scoping reviews. Eligible studies published between 2004 and 2024 in English or with an English translation examining the use of meningitis vaccines and delivery strategies across Africa were included. A systematic search of online databases was conducted using predefined search terms, and following screening of 1,026 articles, 20 were included in the review. Data on relevant themes were extracted into an excel spreadsheet and analyzed guided by PAGER framework.ResultsThe review found limited real-world evidence on meningitis vaccine delivery strategies, with many studies relying on modelling approaches. Findings showed that routine infant immunization and campaign-based strategies have been used to deliver meningitis vaccines in Africa. Compared to routine vaccination, campaign-based strategies were shown to achieve high coverage rates (∼95%), high risk reduction (71%) and high decline in suspected cases (82%). However, routine immunization combined with an initial catch-up campaign was cost-effective, saving USD1.3 for every USD1 invested. The use of the Controlled Temperature Chain (CTC) system for Men A conjugate vaccines enhanced accessibility and cost-effectiveness, particularly for remote facilities lacking cold chain infrastructure. Integrated campaigns were more cost-effective than stand-alone campaigns. Combining campaigns with routine immunization resulted in significant reduction of disease burden, despite potential disruptions during mass vaccination campaigns.ConclusionsCombining routine and campaign-based immunization strategies will enhance the impact of the new meningitis vaccines. There is need for more real-world implementation and cost-effectiveness research from Africa.
2026-08-12 | Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study.
Meningococcal meningitis remains a major public health challenge in Africa's meningitis belt despite the successful elimination of serogroup A epidemics following MenAfriVac introduction. Outbreaks caused by serogroups C, W, and X persist. NmCV-5, a pentavalent conjugate vaccine targeting serogroups A, C, W, Y, and X, was prequalified by WHO in 2023 and used in Niger during reactive vaccination campaigns in 2024. We conducted a matched case-control study in six health districts in Niger (Niamey IV and Magaria) to estimate NmCV-5 effectiveness against meningococcal meningitis. Cases were individuals with PCR-confirmed meningococcal meningitis, aged 1-19 years, resident in the vaccination campaign area, and presenting with symptom onset ≥10 days post-campaign. Enrollment took place between May 2024 and July 2025. Four age-, sex-, and residence-matched community controls were enrolled per case. Vaccination status was verified by patient-retained vaccination card when available or self-reported. Logistic regression was used to calculate crude and adjusted vaccine effectiveness (VE). 17 confirmed cases (14 NmC, 3 NmW) and 68 matched community controls were enrolled in the study. Seven cases (41%) and 58 controls (86%) reported NmCV-5 vaccination; vaccination status of all cases and 8 of 58 (14%) controls was confirmed by vaccination card. Crude VE against all meningococcal meningitis was 88% (95% CI: 62-96), and against NmC specifically was 86% (95% CI: 50-96). Adjusted for household crowding and history of recent respiratory infections, VE was 92% (95% CI: 72-98) overall and 91% (95% CI: 63-98) for NmC. Sensitivity analyses confirmed robustness of estimates under extreme assumptions. NmCV-5 demonstrated high effectiveness against circulating meningococcal strains NmC and NmW in real-world outbreak conditions. Limitations include small sample size, reliance on self-reported vaccination status, and absence of cases from other serogroups. Further studies should assess long-term impact on carriage and effectiveness against invasive disease across all targeted serogroups.
2026-08-06 | A Carriage-Structured Model of Meningococcal Meningitis: Backward Bifurcation, Seasonal Recurrence, and the Reach of Conjugate-Vaccine Strategies in the African Meningitis Belt
Epidemic meningococcal meningitis in the African meningitis belt recurs on two superimposed timescales: a sharp annual dry-season peak and irregular multi-annual epidemics separated by five to twelve years. Because invasive disease is a rare, epidemiologically dead-end outcome of asymptomatic nasopharyngeal carriage, transmission models built on the standard susceptible-infectious template misrepresent the driving process. We formulate a deterministic carriage-structured model in which only carriers transmit, immunity against carriage re-acquisition is leaky, and a conjugate vaccine protects imperfectly and wanes. We show analytically that the basic reproduction number \( R_0 \) is a property of carriage transmission and is decoupled, to first order, from disease incidence, so that reproduction numbers inferred from case notifications estimate the wrong quantity. Using the Castillo-Chavez-Song centre manifold method, we derive, in closed form, the condition for backward bifurcation and prove that it is governed by a threshold \( \varepsilon^\ast \) on carriage-blocking immunity, not by vaccine leakiness or by case-management capacity: the invasive-disease compartment is provably absent from the bifurcation condition. Under seasonal forcing we characterize, through Floquet analysis and two-parameter continuation, the region of immunity-waning and seasonal-amplitude space in which multi-annual recurrence arises, confirming that annual forcing alone cannot generate it. A scenario analysis calibrated to published belt parameter ranges quantifies the burden averted by routine infant immunisation, catch-up campaigns, and improved carriage efficacy, and shows that whether sustained immunisation eliminates epidemics or merely postpones them depends on the same carriage-efficacy threshold that governs bistability.
2026-07-28 | Recent advances in the development of a vaccine to target meningococcal serogroup X.
Serogroup X has emerged as an important cause of invasive meningococcal disease across Sub-Saharan Africa. Recent advances in serogroup X vaccines were reviewed. Early vaccine development efforts focused on outer membrane vesicle-based approaches. The growing epidemiological importance of serogroup X accelerated the development of serogroup X conjugate vaccines. Building on the success of MenAfriVac, PATH and the Serum Institute of India Pvt. Ltd. developed NmCV-5 (MenFive), the first pentavalent meningococcal conjugate vaccine targeting serogroup X. NmCV-5 achieved World Health Organization (WHO) pre-qualification in 2023, enabling deployment across Sub-Saharan Africa. A second pentavalent vaccine, EuNmCV-5, developed by Eubiologics is advancing through clinical development, while an additional candidate from Sinovac Biotech is entering early phase evaluation. These advances representative a major milestone in meningococcal disease prevention. Within the last fifteen years significant vaccine developments have been made to combat serogroup X. With NmCV-5 attaining WHO pre-qualification, strategies for its implementation within Sub-Saharan Africa are being devised. Only one vaccine is currently available in Sub- Saharan Africa, but trials of a second pentavalent ACWYX conjugate vaccine are ongoing. Carriage studies and disease surveillance are crucial to monitor serogroup X vaccine effectiveness.
2026-07-14 | Meningococcal meningitis in India: An expert consensus on use of MCVs.
Invasive meningococcal disease (IMD) is a significant but under-recognized public health challenge in India, marked by rapid progression, high mortality, and severe sequelae. This consensus document, developed from literature review, outbreak analyses, and deliberations by 14 Indian experts, highlights outbreaks from 1966 (Delhi: 616 cases, case fatality ration: CFR 20.9%) to 2022-2023 (Kolkata). Serogroup A remains predominant, with emerging serogroups C, W, and Y. Systematic review evidence shows 12.1% prevalence in epidemics (CFR 12.8%) and 0.76% in endemic settings (CFR 3.0%), though true burden is underestimated due to weak surveillance. IMD shows bimodal age distribution, highest in children < 5 y (61.8%) and adolescents. MenACWY conjugate vaccines show 95.7-99.5% seroprotection across serogroups. Experts recommend vaccination at 9-12 months with booster at 10-11 y, mandatory reporting, sentinel surveillance, and clinician awareness. The roadmap stresses awareness, short-term surveillance, and long-term data generation toward National Immunization Program inclusion.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Meningococcal meningitis.
2 orphan drug designations for Meningococcal meningitis.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Opebacan [Neuprex] | proteins | EMA | 2006-08-28 | — | [INACTIVE] XOMA Ireland Limited |
Recombinant bactericidal/permeability-increasing protein | proteins | FDA | 1998-06-22 | — | Xoma (US) LLC |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.